# Materialise rapporteert resultaten eerste kwartaal 2026
Canonical URL: https://biopharmsignal.com/news/MTLS/materialise-rapporteert-resultaten-eerste-kwartaal-2026
Ticker: MTLS
Company: Materialise
Source: Materialise
Published: 2026-05-08 03:13 EST
Original Source URL: https://investors.materialise.com
## Summary

Materialise draagt eyewear activiteiten over aan het management team Gereglementeerde informatie [1] LEUVEN, België — 7 mei 2026 — Materialise NV (Euronext & NASDAQ: MTLS), een wereldwijde leider in 3D-geprinte medische hulpmiddelen en software en een pionier in additive manufacturing‑software en

## Article Body
Materialise draagt eyewear activiteiten over aan het management team Gereglementeerde informatie [1] LEUVEN, België — 7 mei 2026 — Materialise NV (Euronext & NASDAQ: MTLS), een wereldwijde leider in 3D-geprinte medische hulpmiddelen en software en een pionier in additive manufacturing‑software en
## Recent Company News
- 2026-05-16 02:00 EST — [Materialise houdt jaarlijkse aandeelhoudersvergadering op 16 juni 2026](https://biopharmsignal.com/news/MTLS/materialise-houdt-jaarlijkse-aandeelhoudersvergadering-op-16-juni-2026) — Source: Materialise
- 2026-05-15 20:01 EST — [Materialise to Hold Annual Shareholders’ Meeting on June 16, 2026](https://biopharmsignal.com/news/MTLS/materialise-to-hold-annual-shareholders-meeting-on-june-16-2026) — Source: Materialise
- 2026-05-08 03:13 EST — [Materialise rapporteert resultaten eerste kwartaal 2026](https://biopharmsignal.com/news/MTLS/materialise-rapporteert-resultaten-eerste-kwartaal-2026) — Source: Materialise
- 2026-05-07 05:00 EST — [Materialise Reports First Quarter 2026 Results](https://biopharmsignal.com/news/MTLS/materialise-reports-first-quarter-2026-results) — Source: Materialise
- 2026-04-23 05:00 EST — [Materialise NV to Report First Quarter 2026 Earnings on Thursday, May 7, 2026](https://biopharmsignal.com/news/MTLS/materialise-nv-to-report-first-quarter-2026-earnings-on-thursday-may-7-2026) — Source: Materialise
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)